A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 217 sites in 11 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-01-25.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 20 in phase 3, and was the 7th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,508 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 7th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2013, is one of 121 in phase 3, and was the 177th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously every 4 weeks
Biological: Benralizumab
Benralizumab administered subcutaneously every 8 weeks
Biological: Benralizumab
Placebo administered subcutaneously
Biological: Placebo
Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
Placebo subcutaneously on study week 0 until study week 52 inclusive.
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.
Time frame: Immediately following the first administration of study drug through Study Week 56.
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.
Time frame: Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL
Time frame: Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL
Time frame: Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL
Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL
Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Immediately following the first administration of study drug through Study Week 56.
Change in Asthma Rescue Medication Use
Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)
Time frame: Immediately following the first administration of study drug through Study Week 56.
Home Lung Function Assessments Based on PEF
Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow \[PEF\])
Time frame: Immediately following the first administration of study drug through Study Week 56.
Proportion of Nights With Awakening Due to Asthma
Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma
Time frame: Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
Time frame: Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
Time frame: Immediately following the first administration of study drug through Study Week 56.
Number of Patients With >=1 Asthma Exacerbation
Time frame: Immediately following the first administration of study drug through Study Week 56
Time to First Asthma Exacerbation
Time frame: Immediately following the first administration of study drug through Study Week 56
Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations
Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)
Time frame: Immediately following the first administration of study drug through Study Week 56.
Pharmacokinetics of Benralizumab
Mean PK Concentration at each visit
Time frame: Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60
Immunogenicity of Benralizumab
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Time frame: Pre-treatment until end of follow-up
Extent of Exposure
Extent of exposure is defined as the duration of treatment in days
Time frame: Immediately following the first administration of study drug through Study Week 56
Mean Change From Baseline to Week 56 in AQLQ(S)+12
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.
Time frame: Immediately following the first administration of study drug through Study Week 56
Change From Baseline to Week 56 in EQ-5D-5L VAS
EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
Time frame: Immediately following the first administration of study drug through Study Week 56
Mean Work Productivity Loss Due to Asthma
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.
Time frame: Immediately following the first administration of study drug through Study Week 56
Mean Productivity Loss Due to Asthma in Classroom
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.
Time frame: Immediately following the first administration of study drug through Study Week 56
Number of Participants That Utilized Health Care Resources
Time frame: Immediately following the first administration of study drug through Study Week 56
Patient and Clinician Assessment of Response to Treatment
CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.
Time frame: Immediately following the first administration of study drug through Study Week 56
| Milestone | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Started | 425 | 441 | 440 |
| Completed | 389 | 390 | 402 |
| Not completed | 36 | 51 | 38 |
| Withdrew: Severe non-compliance to protocol | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 8 | 6 |
| Withdrew: Withdrawal by subject | 15 | 27 | 19 |
| Withdrew: Death | 2 | 2 | 1 |
| Withdrew: Adverse event | 4 | 3 | 4 |
| Withdrew: Study specific withdrawal criteria | 0 | 1 | 0 |
| Withdrew: Eligibility criteria not fulfilled | 2 | 0 | 2 |
| Withdrew: Other reasons | 5 | 9 | 4 |
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.
| Events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL | 0.6 (0.48 to 0.74) | 0.66 (0.54 to 0.82) | 0.93 (0.77 to 1.12) |
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.
| Events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL | 0.78 (0.59 to 1.02) | 0.73 (0.55 to 0.95) | 1.21 (0.96 to 1.52) |
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL | 0.34 ± 0.469 | 0.332 ± 0.518 | 0.206 ± 0.471 |
| Liter | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL | 0.221 ± 0.441 | 0.164 ± 0.358 | 0.135 ± 0.437 |
Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL | -1.33 ± 1.23 | -1.4 ± 1.17 | -1.2 ± 1.19 |
Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL | -1.05 ± 1.14 | -0.95 ± 1.13 | -0.88 ± 1.12 |
Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)
| Puffs per day | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change in Asthma Rescue Medication Use | -2.0 ± 3.64 | -2.92 ± 3.60 | -2.65 ± 9.57 |
Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow \[PEF\])
| L/min | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change at Week 56, Morning (n=194, 193, 197) | 41.745 ± 78.534 | 43.375 ± 91.865 | 23.961 ± 71.509 |
| Change at Week 56, Evening (n=194, 192, 197) | 35.142 ± 75.489 | 39.270 ± 89.772 | 15.448 ± 78.341 |
Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma
| Proportion of nights | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Proportion of Nights With Awakening Due to Asthma | -0.373 ± 0.388 | -0.431 ± 0.4 | -0.372 ± 0.405 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL | -1.34 ± 1.13 | -1.49 ± 1.13 | -1.21 ± 1.12 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL | -1.22 ± 1.16 | -1.06 ± 1.02 | -0.83 ± 1.07 |
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Number of Patients With >=1 Asthma Exacerbation | 84 | 95 | 126 |
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Time to First Asthma Exacerbation | 84 | 95 | 126 |
Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)
| Events/year | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations | 0.04 (0.02 to 0.06) | 0.05 (0.03 to 0.08) | 0.04 (0.02 to 0.07) |
Mean PK Concentration at each visit
| ng/mL | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Baseline (n=435, 419) | NA ± NA | NA ± NA | — |
| Week 4 (n=430, 416) | 650.04 ± 154.61 | 703.16 ± 89.48 | — |
| Week 8 (n=414, 395) | 894.86 ± 148.91 | 939.45 ± 98.99 | — |
| Week 16 (n=390, 378) | 936.43 ± 247.46 | 252.54 ± 274.74 | — |
| Week 24 (n=388, 361) | 827.09 ± 370.64 | 188.99 ± 308.38 | — |
| Week 32 (n=345, 323) | 823.21 ± 362.43 | 166.53 ± 289.34 | — |
| Week 40 (n=370, 338) | 859.69 ± 364.28 | 172.28 ± 298.6 | — |
| Week 48 (n=355, 337) | 888.09 ± 333.98 | 186.5 ± 290.28 | — |
| Week 56 (n=358, 344) | 763.98 ± 309.18 | 173.41 ± 235.86 | — |
| Week 60 (n=49, 45) | 53.63 ± 1782.96 | 18.63 ± 756.47 | — |
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Positive at any visit (n=438, 427, 440) | 63 | 64 | 13 |
| Base- and Post-baseline Postive (n=431, 414, 430) | 5 | 5 | 5 |
| Only post-baseline positive (n=431, 420, 436) | 55 | 57 | 8 |
| Persistently positive (n=431, 420, 436) | 44 | 42 | 7 |
| Transient positive (n=431, 420, 436) | 16 | 20 | 6 |
| Only baseline positive (n=438, 421, 434) | 3 | 2 | 0 |
Extent of exposure is defined as the duration of treatment in days
| Days | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Extent of Exposure | 344.14 ± 73.129 | 331.64 ± 88.839 | 336.69 ± 82.148 |
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Change From Baseline to Week 56 in AQLQ(S)+12 | 1.44 ± 1.15 | 1.61 ± 1.24 | 1.32 ± 1.19 |
EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
| Scores on a scale | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Change From Baseline to Week 56 in EQ-5D-5L VAS | 13.8 ± 21.52 | 15.5 ± 20.36 | 12.1 ± 20.13 |
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.
| Percent of productivity loss | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Work Productivity Loss Due to Asthma | 26.56 ± 25.589 | 24.44 ± 24.689 | 27.29 ± 25.802 |
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.
| percent of productivity loss | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Mean Productivity Loss Due to Asthma in Classroom | 19.92 ± 23.765 | 14 ± 16.733 | 33.5 ± 25.593 |
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| Hospitalizations | 11 | 14 | 12 |
| Emergency department visits | 11 | 12 | 18 |
| Unscheduled outpatient visits | 72 | 75 | 83 |
| Home visits | 3 | 1 | 2 |
| Telephone calls | 50 | 63 | 58 |
| Ambulance transports | 2 | 3 | 5 |
CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.
| Participants | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| CGIC, Improved | 109 | 96 | 97 |
| CGIC, Much Improved | 82 | 71 | 65 |
| CGIC, Very Much Improved | 26 | 23 | 14 |
| CGIC, Total | 217 | 190 | 176 |
| PGIC, Improved | 109 | 95 | 99 |
| PGIC, Much Improved | 83 | 80 | 66 |
| PGIC, Very Much Improved | 34 | 30 | 17 |
| PGIC, Total | 226 | 205 | 182 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab 30 mg q.4 Weeks | — | 46/438 (10.5%) | 244/438 (55.7%) |
| Benralizumab 30 mg q.8 Weeks | — | 41/428 (9.6%) | 232/428 (54.2%) |
| Placebo | — | 61/440 (13.9%) | 264/440 (60%) |
| Event | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 21/438 | 19/428 | 23/440 |
| PneumoniaInfections and infestations | 2/438 | 0/428 | 4/440 |
| Pneumonia bacterialInfections and infestations | 2/438 | 0/428 | 3/440 |
| InfluenzaInfections and infestations | 0/438 | 2/428 | 0/440 |
| NephrolithiasisRenal and urinary disorders | 2/438 | 0/428 | 0/440 |
| Myocardial ischaemiaCardiac disorders | 0/438 | 0/428 | 2/440 |
| Acute coronary syndromeCardiac disorders | 0/438 | 1/428 | 0/440 |
| Angina pectorisCardiac disorders | 0/438 | 1/428 | 0/440 |
| Atrial fibrillationCardiac disorders | 0/438 | 1/428 | 0/440 |
| CataractEye disorders | 0/438 | 1/428 | 0/440 |
| Event | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 90/438 | 82/428 | 92/440 |
| BronchitisInfections and infestations | 40/438 | 45/428 | 54/440 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 50/438 | 32/428 | 52/440 |
| Upper respiratory tract infectionInfections and infestations | 29/438 | 37/428 | 42/440 |
| SinusitisInfections and infestations | 23/438 | 21/428 | 39/440 |
| HeadacheNervous system disorders | 33/438 | 34/428 | 32/440 |
| InfluenzaInfections and infestations | 24/438 | 12/428 | 25/440 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 21/438 | 16/428 | 24/440 |
| HypertensionVascular disorders | 12/438 | 18/428 | 22/440 |
| RhinitisInfections and infestations | 12/438 | 18/428 | 17/440 |
| Age, Continuous(Years) | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo | Total |
|---|---|---|---|---|
| Mean | 50.0 ± 13.6 | 49 ± 14.3 | 48.8 ± 15.1 | 49.2 ± 14.3 |
| Gender(Participants) | Benralizumab 30 mg q.4 Weeks | Benralizumab 30 mg q.8 Weeks | Placebo | Total |
|---|---|---|---|---|
| Female | 270 | 273 | 264 | 807 |
| Male | 155 | 168 | 176 | 499 |
Showing the first 100 of 217 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Aug 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab